Digital Health

Digital Health

CVB Digital Health Platform

Biosensors and Mobile Health: Continuous Data Monitoring Platforms

The most devastating effects of brain trauma are rarely observed within the confines of clinics. They take their toll on virtually every function of everyday life: sleepless nights, spontaneous moments of panic, faltering memory, cognition, or mood.

Wearable technologies hold promise in the assessment and continuous monitoring of patients in order to better screen and diagnose, monitor disease progression, and observe intervention response or lack thereof. While monitoring at the pre-diagnosis stage does not require FDA approval, medical-grade data is needed for FDA approval of such platforms for use in medical decision making and data integration is necessary for clinicians’ workflow.

Digital health monitoring also allows us to study brain health and disease in unprecedented ways, by tracking variables such as sleep, physical activity, stress and cognition, we may be able to better understand what changes over time – and to develop earlier and preventive diagnostics and treatments to make a difference in patients’ lives.

CVB Digital Health Platform

 

Early Signal, LLC (EaSi)

Early SignalIn July 2018, we announced the formation of Early Signal, LLC, a wholly owned, non-profit subsidiary. The new subsidiary allows CVB to continue its innovative approach to translational research to advance needed diagnostics and precision medicine for brain disorders and expands our capabilities in digital health and data-driven research.

EaSi is developing a leading digital health platform for recording and analyzing a range of information, reported from wearables and other sensors, directly related to the well-being of patients living with brain disorders. These behavioral, cognitive, physiological and contextual data can be used to quantify brain health, improving the ability of clinicians to diagnosis a wide range of brain disorders and to treat them using precision medicine approaches.

Early Signal’s unique focus on data analysis and development of disease-related algorithms can improve the care that patients receive every day by helping clinicians understand a patient’s unique presentation of disease and tailor their care accordingly.